Repligen signs license deal with Scripps
In Friedreich’s ataxia, low levels of the protein frataxin result in progressive damage to the nervous system and loss of muscle function. Research in tissues derived from patients
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s (BMS) Zenbexus (iberdomide), along with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd), to treat adult multiple myeloma (MM) patients.